摘要
Recent studies have demonstrated the critical role of cardiac-resident macrophages (cMacs) in the maintenance of physiological homeostasis. However, recruitment of circulating monocyte-derived macrophages decreases cMac levels post-myocardial infarction (MI). Transplanting cMacs is not an ideal option due to their low survival rates and the risk of immunological rejection. However, extracellular vesicle therapy has the potential to provide a feasible and safe alternative for cardiac repair. In this study, cell membrane-modified extracellular vesicles (MmEVs) were developed for heart repair by modifying cMac-derived extracellular vesicles (mEVs) with monocyte membranes, resulting in immune evasion and sequential targeted localization to damaged regions through expression of CD47 on MmEVs and strong affinity between monocyte membrane proteins and CCL2. Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin f64 (Tf64) was loaded into the nanoparticles, resulting in Tf64-MmEVs. In vitro experiments indicated that both the MmEVs and Tf64-MmEVs promoted cardiomyocyte proliferation and endothelial cell migration. Animal experiments suggested that MI mice treated with MmEVs and Tf64-MmEVs exhibited reduced myocardial fibrosis and increased vascular density compared to the control group. Thus, we posit that these targeted nanoparticles hold significant potential for MI adjuvant therapy and may open new avenues for cardiac repair and regeneration.Statement of significance Extracellular vesicles (EVs) derived from bioactive parent cell sources involved in pathological and repair processes for cardiovascular disease have emerged as a compelling strategy for regenerative therapy. In this study, we constructed monocyte membrane-modified extracellular vesicles loaded with a drug (Tf64-MmEVs) for heart repair that exhibit extraordinary abilities of immune evasion and sequential localization to damaged regions owing to the presence of CD47 and the strong affinity between monocytes and dam-aged cardiomyocytes and endothelial cells. The bioactivities of Tf64-MmEVs on enhancing cardiomyocyte and endothelial cell proliferation were validated both in vitro and in vivo. Effective development and implementation of therapeutically membrane-modified nanoparticles from homologous origins can provide a reference for adjuvant therapy in clinical MI management.
学科与关键词
- Targeted delivery of extracellular vesicles in heart injuryChen, Peier; Wang, Ling; Fan, Xianglin; Ning, Xiaodong; Yu, Bin; Ou, Caiwen*; Chen, Minsheng*2021, 11(5): 2263-2277.被引 43
- Therapeutic Applications of Extracellular Vesicles for Myocardial RepairLiu, Chunping; Bayado, Nathan; He, Dongyue; Li, Jie; Chen, Huiqi; Li, Longmei; Li, Jinhua; Long, Xinyao; Du, Tingting; Tang, Jing; Dang, Yue; Fan, Zhijin*; Wang, Lei*; Yang, Phillip C.Frontiers in Cardiovascular Medicine, 2021, 8: 758050.被引 20
- Extracellular vesicles engineering by silicates-activated endothelial progenitor cells for myocardial infarction treatment in male miceYu, Bin; Li, Hekai; Zhang, Zhaowenbin; Chen, Peier; Wang, Ling; Fan, Xianglin; Ning, Xiaodong; Pan, Yuxuan; Zhou, Feiran; Hu, Xinyi; Chang, Jiang*; Ou, Caiwen*Nature Communications, 2023, 14(1): 2094.被引 11
